insights_auto
Kāpēc uzņēmuma LILY34 akciju cena ir samazinājusies 4,73%?
Atklājiet vairāk iespējuchevron_right
LILY34:BVMF
Eli Lilly and Company
190,33 R$
arrow_downward
-4,73%(-9,45) 1 d.
8. okt., 11:55:32 GMT-3 · BRL
search
Visi simboli
| Simbols | Cena | Izmaiņas | % izmaiņu |
|---|
insights_autoNotiek galveno ieskatu ģenerēšana par šādu tēmu: LILY34…
Atvērt
199,78 R$
Augsta
199,78 R$
Zema
188,60 R$
Tirgus kapitalizācija
1,08 trilj.
Vid. apjoms
36,66 tūkst.
Apjoms
24,62 tūkst.
Augstākā 52 ned.
223,07 R$
Zemākā 52 ned.
141,56 R$
Apgrozībā esošās akcijas
941,36 milj.
Darbinieku skaits
50 tūkst.
Atvērt
199,78 R$
Augsta
199,78 R$
Zema
188,60 R$
Tirgus kapitalizācija
1,08 trilj.
Vid. apjoms
36,66 tūkst.
Apjoms
24,62 tūkst.
Augstākā 52 ned.
223,07 R$
Zemākā 52 ned.
141,56 R$
Apgrozībā esošās akcijas
941,36 milj.
Darbinieku skaits
50 tūkst.
Ziņas un raksti
No tīmekļa avotiem un ziņu partneriem
Investing.com
·
pirms 31 minūtes
Eli Lilly, Glaukos among market cap stock movers on Thursday
Yahoo Finance
·
pirms 1 stundas
Eli Lilly (LLY) Has a Powerful Growth Flywheel Beyond Its GLP-1 Success
Simply Wall Street
·
pirms 3 stundām
How to invest in healthcare stocks without picking the next Eli Lilly
TradingView
·
pirms 3 stundām
LLY Stock Down 2% in 3 Months: Is the Dip a Buying Opportunity?
Profils
Eli Lilly and Company, doing business as Lilly, is an American multinational pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries. The company was founded in 1876 by Eli Lilly, a pharmaceutical chemist and Union army veteran during the American Civil War for whom the company was later named.
The company is ranked 4th on the list of largest biomedical companies by revenue and is the most valuable pharmaceutical company worldwide. It is ranked 100th on the Fortune 500 and 138th on the Forbes Global 2000. In November 2025, the company reached a $1 trillion market capitalization, the first health-care company in the world to do so.
The company's primary products are tirzepatide for the treatment of type 2 diabetes, weight loss, and obstructive sleep apnea; abemaciclib for the treatment of advanced or metastatic breast cancers; dulaglutide for the treatment of type 2 diabetes; ixekizumab for the treatment of autoimmune diseases; and empagliflozin for the treatment of type 2 diabetes. Wikipedia
Par “Eli Lilly and Company”
ĢenerāldirektorsDavid A. Ricks
Darbinieki50 tūkst.
Dibināšanas datums1876
Galvenais birojsIndianapolisa, Indiāna, Amerikas Savienotās Valstis
Sektors-
Tīmekļa vietnelilly.com